AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** ~~Compound~~ A compound of the formula



(I)

~~where~~wherein:

R_1 is a) hydrogen, hydroxyl or amino; or

b) C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, aryl-C_0-C_4-alkyl or heterocyclyl-C_0-C_4-alkyl, which radicals may be substituted by 1-4 C_1-C_8-alkyl, halogen, oxo, cyano, trifluoromethyl, C_1-C_8-alkoxy, C_1-C_8-alkoxycarbonyl, aryl or heterocyclyl;

R_2 is a) C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkylsulphonyl, C_3-C_8-cycloalkylsulphonyl, aryl-C_0-C_8-alkylsulphonyl, heterocyclylsulphonyl, C_3-C_{12}-cycloalkyl-C_1-C_8-alkanoyl, aryl-C_1-C_8-alkanoyl, aryl-C_3-C_8-cycloalkanoyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, optionally N-mono- or N,N-di-C_1-C_8-alkylated carbamoyl-C_0-C_8-alkyl, aryl-C_0-C_4-alkyl or heterocyclyl-C_0-C_4-alkyl, which radicals may be substituted by 1-4 C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_3-C_8-cycloalkoxy, amino, $C_{1\text{-}6}$-alkylamino, di-$C_{1\text{-}6}$-alkylamino, C_1-C_6-alkanoylamino, C_1-C_8-alkoxycarbonylamino, halogen, oxo, cyano, hydroxyl, trifluoromethyl, C_1-C_8-alkoxy, C_1-C_8-alkoxycarbonyl, aryl or heterocyclyl; or

b) together with R_1 and the nitrogen atom to which they are bonded is a saturated or partly unsaturated, 4-8-membered, heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or an -SO- or -SO2- group, and the additional nitrogen atom may optionally be substituted by C_1-C_8-alkyl; C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, aryl or heteroaryl radicals, in which case this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 members and the second ring may also contain a nitrogen, oxygen or sulphur atom or an -SO- or -SO2- group, and the nitrogen atom of the second ring may optionally be substituted by C_1-C_8-alkyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, aryl or heterocyclyl radicals, and all ring systems mentioned may be substituted by 1-4 C_1-C_8-alkyl,

halogen, hydroxyl, oxo, trifluoromethyl, C_1-C_8-alkoxy, C_1-C_8-alkoxy-C_1-C_8-alkyl, C_1-C_8-alkoxy-C_1-C_8-alkoxy, C_1-C_8-alkoxycarbonylamino, C_1-C_8-alkanoylamino, C_1-C_8-alkylamino, N,N-di-C_1-C_8-alkylamino, aryl-C_0-C_4-alkyl, aryloxy-C_0-C_4-alkyl, aryl-C_0-C_4-alkyl-C_1-C_8-alkoxy, aryloxy-C_0-C_4-alkyl-C_1-C_8-alkoxy, heterocyclyl-C_0-C_4-alkyl, heterocyclyloxy-C_0-C_4-alkyl, heteroaryl-C_0-C_4-alkyl-C_1-C_8-alkoxy or heterocyclyloxy-C_0-C_4-alkyl-C_1-C_8-alkoxy;

R_3 is hydrogen, C_1-C_4-alkyl, C_1-C_8-alkoxycarbonyl or C_1-C_8-alkanoyl;

R_4 is hydrogen, C_1-C_4-alkyl, C_1-C_8-alkoxycarbonyl or C_1-C_8-alkanoyl;

R_5 is in each case independently hydrogen, C_1-C_8-alkyl, or, together with the carbon atom to which they are bonded, are a C_3-C_8-cycloalkylidene radical;

R_6 is hydrogen or hydroxyl;

R, in each case independently, are 1-4 radicals selected from:

hydrogen, halogen, C_1-C_8-alkyl, 3- to 8-membered cycloalkyl, polyhalo-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkoxy-C_1-C_4-alkyl, 3- to 8-membered cycloalkoxy-C_1-C_4-alkyl, hydroxyl, C_1-C_8-alkanoyloxy-C_1-C_4-alkyl, hydroxy-C_2-C_8-alkyl, C_1-C_4-alkylthio-C_1-C_4-alkyl, C_1-C_8-alkylsulphonyl-C_1-C_4-alkyl, thiazolylthio-C_1-C_4-alkyl, thiazolinylthio-C_1-C_4-alkyl, imidazolylthio-C_1-C_4-alkyl, optionally N-oxidized pyridylthio-C_1-C_4-alkyl, pyrimidinylthio-C_1-C_4-alkyl, optionally partially hydrogenated pyridyl- or N-oxidopyridyl-C_1-C_4-alkyl, C_1-C_4-alkylsulphonylamino-C_1-C_4-alkyl, trifluoro-C_1-C_8-alkylsulphonylamino-C_1-C_4-alkyl, pyrrolidino-C_1-C_4-alkyl, piperidino-C_1-C_4-alkyl, piperazino-C_1-C_4-alkyl, N'-C_1-C_4-alkylpiperazino-C_1-C_4-alkyl, N'-C_2-C_8-alkanoylpiperazino-C_1-C_4-alkyl, morpholino-C_1-C_4-alkyl, thiomorpholino-C_1-C_4-alkyl, S-oxothiomorpholino-C_1-C_4-alkyl, S.S-dioxothiomorpholino-C_1-C_4-alkyl, cyano-C_1-C_4-alkyl, carboxy-C_1-C_4-alkyl, C_1-C_4-alkoxycarbonyl-C_1-C_4-alkyl, carbamoyl-C_1-C_8-alkyl, N-mono- or N,N-di-C_1-C_4-alkylcarbamoyl-C_1-C_4-alkyl, unsubstituted or mono-, di- or tri-C_1-C_4-alkyl-, -C_1-C_4-alkoxy-, -hydroxy-, -C_1-C_4-alkylamino-, -di-C_1-C_4-alkylamino-, -halogen- or -trifluoromethyl-substituted phenyl or naphthyl, hydroxy-C_2-C_8-alkoxy, halo-C_2-C_8-(hydroxy)alkoxy, C_1-C_8-alkylsulphonyl-C_1-C_4-(hydroxy)alkoxy, amino-C_1-C_4-alkyl, C_1-C_4-alkylamino-C_1-C_4-alkyl, N, N-di-C_1-C_4-alkylamino-C_1-C_4-alkyl, N-C_1-C_4-alkanoylamino-C_1-C_4-alkyl, C_1-C_8-alkoxycarbonylamino-C_1-C_4-alkyl, optionally partially hydrogenated pyridyl- or N-oxidopyridyl-C_1-C_4-alkyl, piperazino-C_1-C_4-alkyl, N'-C_1-C_4-alkylpiperazino-C_1-C_4-alkyl, N'-C_2-C_8-alkanoylpiperazino-C_1-C_4-alkyl, morpholino-C_1-C_4-alkyl, thiomorpholino-C_1-C_4-alkyl,

S-oxothiomorpholino-C_1-C_4-alkyl, S,S-dioxothiomorpholino-C_1-C_4-alkyl, amino-C_1-C_4-alkoxy, C_1-C_4-alkylamino-C_1-C_4-alkoxy, N,N-di-C_1-C_4-alkylamino-C_1-C_4-alkoxy, C_1-C_4-alkanoyl-amino-C_1-C_4-alkoxy, C_1-C_8-alkoxycarbonylamino-C_1-C_4-alkoxy, C_1-C_8-alkanoyl-C_2-C_4-alkoxy which bears the alkanoyl group in a position higher than the α-position, C_1-C_8-alkoxy, 3- to 8-membered cycloalkoxy, C_2-C_8-alkenyloxy, 3- to 8-membered cycloalkoxy-C_1-C_4-alkoxy, C_1-C_8-alkoxy-C_1-C_8-alkoxy, C_1-C_4-alkoxy-C_2-C_4-alkenyl, C_2-C_8-alkenyloxy-C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_2-C_4-alkenyloxy, C_2-C_8-alkenyloxy-C_1-C_4-alkyl, C_1-C_4-alkylthio-C_1-C_4-alkoxy, C_1-C_8-alkylsulphonyl-C_1-C_4-alkoxy, C_1-C_4-alkylthio-C_1-C_4-(hydroxy)alkoxy, unsubstituted or mono-, di- or tri-C_1-C_4-alkyl-, -C_1-C_4-alkoxy-, -hydroxy-, -C_1-C_4-alkylamino-, -di-C_1-C_4-alkylamino-, -halo- and/or -trifluoromethyl-substituted phenyl- or naphthyl-C_1-C_4-alkoxy, polyhalo-C_1-C_4-alkoxy, optionally partially hydrogenated pyridyl- or N-oxidopyridyl-C_1-C_4-alkoxy, thiazolyl-C_1-C_4-alkoxy, optionally N-oxidized morpholino-C_1-C_4-alkoxy, thiazolylthio-C_1-C_4-alkoxy, thiazolinylthio-C_1-C_4-alkoxy, imidazolylthio-C_1-C_4-alkoxy, optionally N-oxidized pyridylthio-C_1-C_4-alkoxy, pyrimidinylthio-C_1-C_4-alkoxy, amino-C_1-C_4-alkoxy, C_1-C_4-alkylamino-C_1-C_4-alkoxy, N,N-di-C_1-C_4-alkylamino-C_1-C_4-alkoxy, C_1-C_8-alkanoylamino-C_1-C_4-alkoxy, C_1-C_8-alkylsulphonylamino-C_1-C_4-alkoxy, trifluoro-C_1-C_8-alkylsulphonyl-C_1-C_4-alkoxy, pyrrolidino-C_1-C_4-alkoxy, piperidino-C_1-C_4-alkoxy, cyano-C_1-C_4-alkoxy, carboxy-C_1-C_4-alkoxy, C_1-C_4-alkoxycarbonyl-C_1-C_4-alkoxy, carbamoyl-C_1-C_4-alkoxy, N-C_1-C_8-alkylcarbamoyl-C_1-C_4-alkoxy or N-mono- or N,N-di-C_1-C_4-alkylcarbamoyl-C_1-C_4-alkoxy, carboxy-C_1-C_4-alkyl, C_1-C_4-alkoxycarbonyl-C_1-C_4-alkyl, carbamoyl-C_1-C_8-alkyl, N-mono- or N,N-di-C_1-C_4-alkylcarbamoyl-C_1-C_4-alkyl, carboxy-C_1-C_4-alkoxy, C_1-C_4-alkoxycarbonyl-C_1-C_4-alkoxy, carbamoyl-C_1-C_8-alkoxy, N-Mono- or N,N-di-C_1-C_4-alkylcarbamoyl-C_1-C_4-alkoxy, C_1-C_4-alkylamino or N,N-di-C_1-C_4-alkylamino,

or salt or prodrug thereof, or where one or more atoms are replaced by their stable, non-radioactive isotopes, preferably pharmaceutically usable salt thereof.

2. (Currently amended) ~~Compound~~ The compound according to Claim 1, ~~where~~wherein:

R_1 is a) hydrogen; or

b) C_1-C_8-alkyl or C_3-C_8-cycloalkyl;

R_2 is a) C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkanoyl, heterocyclyl-C_1-C_8-alkanoyl, C_3-C_{12}-cycloalkyl-C_1-C_8-alkanoyl or aryl-C_1-C_8-alkanoyl, which radicals may be substituted by 1-4 C_1-C_8-alkyl, C_{1-6}-alkylamino, cyano, halogen, hydroxyl, C_1-C_6-alkanoylamino, C_1-C_8-alkoxy, oxo, trifluoromethyl or aryl; or

b) together with R_1 and the nitrogen atom to which they are bonded are a saturated or partly unsaturated, 4-8-membered, heterocyclic ring which may contain an additional nitrogen or oxygen atom, in which case the additional nitrogen atom may optionally be substituted by C_1-C_8-alkyl or C_1-C_8-alkanoyl, and this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 ring members and the second ring may also contain a nitrogen or oxygen atom, in which case the nitrogen atom of the second ring may optionally be substituted by C_1-C_8-alkyl or C_1-C_8-alkanoyl, and all ring systems mentioned may be substituted by 1-4 C_1-C_8-alkyl, hydroxyl, oxo, C_1-C_8-alkoxy, C_1-C_8-alkoxy-C_1-C_8-alkoxy, C_1-C_8-alkanoylamino or aryloxy-C_0-C_4-alkyl-C_1-C_8-alkoxy;

R_3 is hydrogen;

R_4 is hydrogen;

R_5 are each independently hydrogen or C_1-C_8-alkyl;

R_6 is hydrogen;

R are each independently 1-4 radicals selected from:
hydrogen, C_1-C_8-alkyl, halogen, trifluoromethyl, C_1-C_4-alkoxy-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkoxy-C_1-C_4-alkyl, C_1-C_8-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkoxy,

or pharmaceutically usable salt thereof.

3. (Currently amended) ~~Compound~~ The compound according to Claim 1 of the formula



(Ia)

~~where~~wherein R, R_1, R_2, R_3, R_4 and R_5 are each as defined in Claim 1.

4. (Currently amended) ~~Compound~~ The compound according to Claim 1,

~~where~~wherein R_2 together with R_1 and the nitrogen atom to which they are bonded is a substituted or unsubstituted heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, pyridinyl, piperazino, morpholino, thiomorpholino, furanyl, tetrahydrofuranyl, pyranyl, tetrahydropyranyl, thiazolyl, oxazolyl, imidazolyl, indolinyl, isoindolinyl, 2,3-dihydrobenzimidazolyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, 1,2,3,4-tetrahydro-1,3-benzodiazinyl, 1,2,3,4-tetrahydro-1,4-benzodiazinyl, 3,4-dihydro-2H-1,4-benzoxazinyl, 3,4-dihydro-2H-1,4-benzothiazinyl, 3,4-dihydro-2H-1,3-benzothiazinyl, 3,4,5,6,7,8-hexahydro-2H-1,4-benzoxazinyl, 3,4,5,6,7,8-hexahydro-2H-1,4-benzothiazinyl, 9-azabicyclo[3.3.1]non-9-yl, 1-azepan-1-yl, 2,8-diazaspiro[4.5]dec-8-yl, octahydroisoindol-2-yl, 4-azatricyclo[5.2.1.$0^{2,6}$]dec-4-yl, 3-azabicyclo[3.2.1]oct-3-yl, 3,7-diazabicyclo[3.3.1]non-3-yl, 3-azabicyclo[3.3.1]non-3-yl, 8-azabicyclo[3.2.1]oct-8-yl, 3-azabicyclo[3.2.2]non-3-yl, 2,3,4,5-tetrahydro-1H-1-benz[6,7-b]azepinyl and 5,6-dihydrophenanthridinyl.

5. (Cancelled)

6. (Currently amended) ~~Pharmaceutical~~ A pharmaceutical preparation comprising, as an active pharmaceutical ingredient, a compound according to Claim 1 in free form or as a pharmaceutically usable salt, and a pharmaceutically acceptable excipient.

7. (Cancelled)

8. (Withdrawn-currently amended) ~~Use of a compound according to Claim 1 for the preparation of a pharmaceutical preparation for the~~ A method for the treatment ~~or prevention~~ of a condition selected from the group consisting of hypertension, heart failure, glaucoma, cardiac infarction, kidney failure ~~or~~ and restenosis, said method comprising administering a compound according to Claim 1, or a salt or prodrug thereof, to a patient in need thereof.

9. (Currently amended) ~~Pharmaceutical~~ A pharmaceutical preparation comprising, as an active pharmaceutical ingredient, a compound according to Claim 2 in free form or as a pharmaceutically usable salt, and a pharmaceutically acceptable excipient.

10. (Currently amended) ~~Pharmaceutical~~ A pharmaceutical preparation comprising, as an active pharmaceutical ingredient, a compound according to Claim 3 in free form or as a pharmaceutically usable salt, and a pharmaceutically acceptable excipient.

11. (Currently amended) ~~Pharmaceutical~~ A pharmaceutical preparation comprising, as an active pharmaceutical ingredient, a compound according to Claim 4 in free form or as a pharmaceutically usable salt, and a pharmaceutically acceptable excipient.